Semaglutide linked to 20% fewer COPD flare-ups and nearly 40% fewer asthma attacks
The diabetes and weight-loss injection semaglutide can reduce asthma attacks by up to 40%, according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain. The study was led by Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.
A recent study presented at the European Respiratory Society Congress in Barcelona has found that the diabetes and weight-loss injection semaglutide can reduce asthma attacks by up to 40% and nearly 40% fewer COPD flare-ups. Conducted using UK electronic medical records, the research led by Chloe Bloom and presented by Dr. Bohee Lee, found that people with asthma or COPD who were prescribed GLP-1 therapies had fewer respiratory attacks and flare-ups compared to those prescribed other diabetes medications.
While the findings are encouraging, they should not alter treatment decisions as more clinical trials are needed to confirm these results. The study highlights the importance of considering metabolic health in respiratory care and suggests that future trials should include respiratory outcomes.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
